PXVX0200 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cholera
Conditions
Cholera
Trial Timeline
Apr 1, 2012 → Jan 1, 2013
NCT ID
NCT01585181About PXVX0200 + Placebo
PXVX0200 + Placebo is a phase 1 stage product being developed by Bavarian Nordic for Cholera. The current trial status is completed. This product is registered under clinical trial identifier NCT01585181. Target conditions include Cholera.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02100631 | Phase 3 | Completed |
| NCT01895855 | Phase 3 | Completed |
| NCT01585181 | Phase 1 | Completed |
Competing Products
9 competing products in Cholera
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Azithromycin | Pfizer | Phase 3 | 76 |
| Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell | Sanofi | Phase 3 | 76 |
| Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell | Sanofi | Approved | 84 |
| Ciprofloxacin | Bayer | Phase 3 | 74 |
| PXVX0200 + placebo | Bavarian Nordic | Phase 3 | 74 |
| PXVX0200 + Placebo | Bavarian Nordic | Phase 3 | 74 |
| VAXCHORA (Cholera Vaccine, Live, Oral) | Bavarian Nordic | Approved | 82 |
| PXVX0200 Lot A + PXVX0200 Lot B + PXVX0200 Lot C + Placebo | Bavarian Nordic | Phase 3 | 74 |
| PXVX0200 10E8 + PXVX0200 10E9 + Placebo + Shanchol | Emergent BioSolutions | Phase 2 | 44 |